LIBERTEX/ARBITRUM
17.5.2023 09:08:28 CEST | Business Wire | Press release
Libertex, the online trading platform for retail and professional traders, has just launched an exciting new underlying asset that grants traders a superb opportunity to trade the future of cryptocurrency – Arbitrum CFDs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005969/en/
(Graphic: Business Wire)
About Arbitrum
Arbitrum is a layer-2 scaling solution for Ethereum that runs its own blockchain. Designed to improve upon the base Ethereum functionality that supports smart contracts, NFTs and dApps, Arbitrum is creating a buzz among crypto and institutional investors in the finance world because of the advantages it offers compared to older crypto solutions. These include:
- Faster transactions – Arbitrum can process 40,000 transactions per second compared to just 14 on Ethereum. This makes it much more capable of upscaling than Ethereum and its competitors.
- Lower fees – Due to its highly efficient optimistic rollup technology, transactions that would cost several dollars to complete on Ethereum only cost around two cents on Arbitrum.
- Market share – Arbitrum's appeal is backed up by the numbers. It is the leading layer-2 solution, claiming over 66% of the market in terms of total value locked. There are over 4 million unique Arbitrum addresses and more than 400 Arbitrum dApps, including many popular platforms such as GMX, Uniswap and Camelot.
- Developer-friendly – Arbitrum is fully compatible with the Ethereum Virtual Machine (EVM) and popular programming languages. It comes with documentation for developers and doesn't need any plugins or extras for developing Ethereum-based apps.
- Governance functionality – Arbitrum tokens (ARB) will be used for governance within the Arbitrum DAO, granting holders a voice and stake in the future of the project.
- Track NFTs in real time – The latest feature to be added to Arbitrum is the ability to receive real-time notifications when an NFT changes addresses, as well as the option to track and follow trends using the Alchemy platform. This makes it especially useful for anyone involved in the NFT marketplace.
Arbitrum continues to add new features that make it an even bigger player in the crypto world. Traders now have a chance to join this project's exciting journey by trading Arbitrum CFDs with Libertex without needing to buy or hold the ARB token itself.
Trade for More with Libertex
Recognising the importance of cryptocurrency as an exciting new industry sector for traders, Libertex features no commissions, swap or exchange fees and ultra-low spreads on all crypto CFDs, making it one of the best places to trade crypto CFDs. To find out more about Libertex, visit libertex.com or download the mobile app for iOS on the App Store or for Android on Google Play or AppGallery.
Part of the Libertex Group, Libertex is an online broker offering tradable CFDs with underlying assets being commodities, Forex, ETFs, cryptocurrencies and others. Libertex also offers investments in real stocks.
Over the years, Libertex has received more than 40 prestigious international awards and recognitions, including "Best CFD Broker Europe" (Global Brands Magazine, 2022) and "Most Trusted Broker in Europe" (Ultimate Fintech Awards, 2021). Libertex is the Official Online Trading Partner of FC Bayern and Tottenham Hotspur, bringing the exciting worlds of football and trading together.
Since being founded in 1997, the Libertex Group has grown into a diverse group of companies, serving millions of clients from several countries all over the world.
In Europe, the Libertex trading platform is operated by Indication Investments Ltd., a Cyprus Investment Firm regulated and supervised by the Cyprus Securities and Exchange Commission (CySEC) with CIF License number 164/12.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.9% of retail investor accounts lose money when trading CFDs with this provider. Tight spreads apply. Please check our spreads on the platform. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005969/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom